Company Snapshot
- Ticker
- VRTX
- Name
- VRTX
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 116479476000.000000
- Volume
- 1,336,865
- Avg Volume (3M)
- 1,535,157
VRTX
VRTX
Last update recent
455.71
+3.67
(+0.81%)
Market Cap
116479476000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 11723300000.000000
- EPS
- 14.33
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- 3675100000.000000
- Net Margin
- 31.35%
- Payout Ratio
- 0.0%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 31.69
- Forward P/E
- None
- P/S
- 9.94
- P/B
- 6.73
- Beta
- None
- Debt / Equity
- 0.11
- Current Ratio
- 2.36
- Return on Equity
- 0.21%
- Return on Assets
- 0.15%
Technicals & Returns
- Distance vs 200 DMA
- 3.14%
- 200 DMA
- 441.82
- Distance vs 50 DMA
- 6.73%
- 50 DMA
- 426.98
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated foc Read more
- Name
- VRTX
- Industry
- Biotechnology
- CEO
- Dr. Reshma Kewalramani FASN, M.D.
- Employees
- 5,400
- IPO Date
- 1991-07-24
- Phone
- 617 341 6100
- Address
- None
- Website
- https://www.vrtx.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
12 Days of Investing: My Top 12 Stocks to Buy Before 2026
There are only 12 investing days left in 2025. Now is a great time to load up on stocks that may win next year -- and over time.
Castleark Management LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Castleark Management LLC trimmed its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 98.4% during the undefined quarter, according to the compan…
Ameriprise Financial Inc. Sells 54,107 Shares of Vertex Pharmaceuticals Incorporated $VRTX
Ameriprise Financial Inc. lowered its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 2.4% in the undefined quarter, according to i…
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's pro…
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Apple's fiercely loyal customer base gives it a built-in market for any new devices it might launch in the future. MercadoLibre is positioned to grow rapidly i…
Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.